STOCK TITAN

KHIRON LIFE SCIENCES CORP - KHRNF STOCK NEWS

Welcome to our dedicated page for KHIRON LIFE SCIENCES news (Ticker: KHRNF), a resource for investors and traders seeking the latest updates and insights on KHIRON LIFE SCIENCES stock.

Khiron Life Sciences Corp, traded as KHRNF, is a prominent global medical cannabis firm with operations in Latin America and Europe. With fully-owned medical health clinics and exclusive telemedicine platforms, Khiron integrates a patient-centered approach, physician education programs, scientific proficiency, product innovation, and accessibility creation to increase prescriptions and brand loyalty among patients worldwide. The company operates in Colombia, Germany, the UK, Switzerland, Peru, and Brazil. Led by CEO Alvaro Torres, Khiron is supported by a seasoned executive team and board of directors.

Rhea-AI Summary

Khiron Life Sciences Corp. has partnered with the Colombia Cancer League and 21 medical institutions to launch the "Cannabis: Medicine for Your Life" campaign. This initiative will provide over 3,000 free consultations for chronic pain, palliative care, and oncology patients across 11 Colombian cities. Khiron has seen over 120% growth in medical cannabis prescriptions filled, totaling over 18,000 to date, with gross margins exceeding 80%. The campaign aims to enhance patient access to safe medical cannabis treatments and expand awareness among healthcare providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
Rhea-AI Summary

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) will hold a conference call on May 28, 2021, at 10:00 a.m. ET to discuss its first-quarter financial results for the period ending March 31, 2021. The call will feature presentations from CEO Alvaro Torres, CFO Joel Friedman, and Chairman Chris Naprawa, followed by a Q&A session. Khiron has also engaged Stonebridge Partners LLC for investor relations services at a fee of USD $5,000 per month, with mutual renewal options. For more details, visit investors.khiron.ca.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences
-
Rhea-AI Summary

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) has highlighted findings from Project Twenty21, the UK's largest observational study on medical cannabis, published in 'Psychopharmacology'. The study shows significant improvements in quality of life for patients with chronic conditions, including a 50% increase in self-reported health among participants. Over 900 patients have accessed legal medical cannabis, avoiding chronic pain and dependency on traditional drugs. Khiron aims to expand its initiatives to enhance patient access and continues to lead in cannabis education.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
Rhea-AI Summary

Khiron Life Sciences Corp. announced that its Chairman, Chris Naprawa, will present at Canaccord Genuity's 2021 Virtual Cannabis Conference on May 11, 2021, at 1:00 p.m. EDT. The company has seen a significant increase in prescription fills, with a 135% rise in Q1 2021 compared to 2020, largely due to newly introduced medical cannabis insurance in Colombia. Khiron has a strong market presence in Latin America and Europe, delivering its first EU-GMP certified medical cannabis shipment to Germany. For more details, visit investors.khiron.ca.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
-
Rhea-AI Summary

Khiron Life Sciences Corp. reported a 31% sequential growth in Q4 2020, with revenues reaching $2.5 million, driven by increased medical cannabis sales and normalized clinic operations. Medical cannabis insurance coverage in Colombia, effective December 2020, has significantly boosted growth, with 7,500 prescriptions filled in Q1 2021. The company maintains strong cash reserves of $21.6 million. Despite a net loss of $24 million for 2020, management remains optimistic about future growth in Latin America and Europe, with plans to expand clinic operations and product sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.66%
Tags
-
Rhea-AI Summary

Khiron Life Sciences Corp. has achieved UK Continuing Professional Development (CPD) accreditation for its educational platform, Khiron Academy, enabling UK medical professionals to earn CPD credits through medical cannabis training. The company has partnered with Cellen Therapeutics to enhance patient access to cannabis education. To date, nearly 1,000 medical professionals in Latin America and the UK have completed training, leading to over 13,000 prescriptions issued by physicians trained by Khiron, reflecting a compound monthly growth rate of 50%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none
Rhea-AI Summary

Khiron Life Sciences Corp. has announced an operational update emphasizing its expansion in the UK medical cannabis market. Following a successful launch in Germany, the company plans to introduce Khiron 1/14, a high-CBD flower, for UK patients in Q2 2021. This product will complement its existing high-THC offering and aims to increase patient access through improved supply chains. Khiron is also enhancing its product portfolio by exporting additional cannabis-based medical products from Colombia, thereby improving availability for patients in the UK.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
-
Rhea-AI Summary

Khiron Life Sciences Corp. has successfully completed its first shipment of EU-GMP certified medical cannabis to Germany, targeting immediate access through its distribution partner Nimbus Health GmbH. The launch product, Khiron 1/14 high-CBD flower, aims to address medical needs such as anxiety, substance use disorder, and migraines. With a distribution network spanning over 300 pharmacies in Germany, Khiron is positioned to establish a significant market presence. The company's ongoing education efforts for physicians further enhance its strategy in this growing market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.89%
Tags
none
-
Rhea-AI Summary

Khiron Life Sciences Corp. announced the opening of two new satellite Zerenia™ clinics in Cali and Bucaramanga, Colombia, expanding its network to six clinics. This expansion follows a successful start to 2021, with paid prescriptions surpassing total prescriptions from 2020. The company plans to open additional satellite clinics throughout Colombia, enhancing patient access to medical cannabis. CEO Alvaro Torres aims to reach 1 million patients by 2024, leveraging positive feedback from existing clinics to support this growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
Rhea-AI Summary

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) announced that CEO Alvaro Torres will participate in the Q1 Virtual Investor Summit from March 23-25, 2021. The company's presentation is scheduled for March 24 at 1:00 PM ET. The Investor Summit connects smallcap companies with investors and will feature over 100 companies and 300 institutional and retail investors. Khiron is a leading medical cannabis provider in Colombia and is set to expand its operations into Germany and Brazil this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.19%
Tags
conferences

FAQ

What is the current stock price of KHIRON LIFE SCIENCES (KHRNF)?

The current stock price of KHIRON LIFE SCIENCES (KHRNF) is $0.000001 as of May 17, 2024.

What is the market cap of KHIRON LIFE SCIENCES (KHRNF)?

The market cap of KHIRON LIFE SCIENCES (KHRNF) is approximately 6.2M.

What is Khiron Life Sciences Corp known for?

Khiron is a leading global medical cannabis company with operations in Latin America and Europe.

Where does Khiron have a sales presence?

Khiron has a sales presence in Colombia, Germany, the UK, Switzerland, Peru, and Brazil.

Who leads Khiron Life Sciences Corp?

Khiron is spearheaded by CEO Alvaro Torres, along with an experienced executive team and board of directors.

What sets Khiron apart in the medical cannabis industry?

Khiron focuses on a patient-oriented approach, physician education programs, scientific expertise, product innovation, and accessibility creation.

What are Khiron's core operations?

Khiron's core operations include wholly-owned medical health clinics and proprietary telemedicine platforms.

Which regions does Khiron primarily operate in?

Khiron primarily operates in Latin America and Europe.

How does Khiron drive prescriptions and brand loyalty?

Khiron drives prescriptions and brand loyalty through a patient-centered approach and product innovation.

What recent achievement did Khiron announce?

Khiron announced the Restated Purchase Agreement for the sale of its European subsidiaries.

Who controls 2518542 Alberta Ltd?

2518542 Alberta Ltd is controlled by Avonlea Drewry Holdings Inc.

What is the Manager Expenses for the Management Services?

The Manager Expenses is a management fee equal to the monthly net income of the Subject Subsidiaries, plus reasonable expenses.

KHIRON LIFE SCIENCES CORP

OTC:KHRNF

KHRNF Rankings

KHRNF Stock Data

6.23M
228.14M
0.22%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Vancouver